RedHill Biopharma Ltd (ADR) - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
RDHL Nasdaq 2836 https://www.redhillbio.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for RedHill Biopharma Ltd (ADR)

RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study - Apr 24th, 2024 11:00 am
RedHill Biopharma Full Year 2023 Earnings: EPS: US$4.00 (vs US$46.29 loss in FY 2022) - Apr 10th, 2024 10:23 am
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights - Apr 8th, 2024 1:00 pm
RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price - Apr 2nd, 2024 11:00 am
RedHill Announces New USPTO Patent Covering Talicia® Through 2034 - Mar 11th, 2024 11:00 am
RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs - Mar 5th, 2024 12:00 pm
RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication - Feb 20th, 2024 12:00 pm
RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering - Jan 26th, 2024 5:46 pm
RedHill Biopharma Announces $8 Million Registered Direct Offering - Jan 25th, 2024 2:05 pm
RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042 - Jan 25th, 2024 11:00 am
RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola - Dec 20th, 2023 1:45 pm
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement - Dec 12th, 2023 12:00 pm
RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study - Dec 4th, 2023 12:00 pm
RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034 - Nov 27th, 2023 12:00 pm
RedHill Biopharma Announces the Transfer of its Listing to The Nasdaq Capital Market - Nov 14th, 2023 1:00 pm
RedHill and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo Study - Oct 3rd, 2023 11:00 am
RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency - Sep 22nd, 2023 8:15 pm
RedHill Announces FDA sNDA Approval for Talicia® - Sep 18th, 2023 11:00 am
RedHill Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA®) - Sep 5th, 2023 11:00 am
RedHill Biopharma Provides H1/23 Financial Results and Operational Highlights - Aug 17th, 2023 11:00 am